Rigel Pharmaceuticals Unveils Data at 2026 ASCO and EHA Congresses on Cancer Treatments

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a clinical-stage biotech firm specializing in hematologic disorders and oncology, has announced the details of its presentations for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress.

Set to take place from May 29 to June 2 in Chicago, Illinois, the ASCO Annual Meeting will showcase the final findings from Rigel’s Phase 3 AcceleRET-Lung clinical trial. This trial evaluated GAVRETO® (pralsetinib) as a first-line therapy for RET fusion-positive non-small cell lung cancer (NSCLC). The oral presentation will highlight GAVRETO's efficacy, showing it met primary progression-free survival (PFS) endpoints and outperformed standard treatment options with notable improvements in overall response rates and response duration.

Additionally, Rigel will present critical data regarding its other significant drug, REZLIDHIA® (olutasidenib), during poster sessions at both conferences. This data will focus on its use in treating relapsed or refractory (R/R) isocitrate dehydrogenase-1 (mIDH1)-mutated acute myeloid leukemia (AML). The presentations are part of Rigel's commitment to establishing a robust portfolio that addresses complex oncologic conditions.

Key Details from the Presentations

1. ### GAVRETO Outcomes at ASCO
- In the Phase 3 AcceleRET study, pralsetinib demonstrated remarkable efficacy in achieving PFS compared to traditional treatments. The drug also showcased a favorable safety profile. Notably, despite some serious infection risks associated with treatment (with 30% presenting serious adverse events), proactive monitoring can manage these effectively.

2. ### Long-term Efficacy for REZLIDHIA
- The presentations will detail findings from the Phase 1/2 ARROW trial focusing on patients with RET-altered thyroid cancer. Here, pralsetinib yielded effective, durable responses without the need for more aggressive treatments.
- Regarding REZLIDHIA, clinical data revealed that it facilitated long-term complete response rates in a significant number of patients with R/R mIDH1 AML, showcasing a 74% estimated overall survival rate over 48 months and marking substantial improvements in patient quality of life.

3. ### Real-World Data
- Real-world observations involving 51 patients who transitioned to olutasidenib after a venetoclax regimen indicated a 60.8% complete response rate and a remarkably extended median response duration, indicating that early incorporation of REZLIDHIA into treatment planning may enhance outcomes for these patients.

4. ### Broader Implications
- Rigel's presentations underscore its dedication to advancing therapeutic options for patients battling aggressive cancer forms. With the ASCO and EHA providing platforms for these findings, Rigel aims to reinforce its reputation as a leader in oncology by demonstrating the potential of its targeted therapies to transform treatment landscapes.

Conclusion

Rigel Pharmaceuticals is excited to present its findings at two of the prominent medical conferences in the oncology field. With emerging data showcasing the utility and effectiveness of GAVRETO and REZLIDHIA, the company solidifies its commitment to innovative therapies that significantly impact patient outcomes in challenging cancer cases. These developments underline not only Rigel's progress in clinical trials but also its enduring resolve to improve the quality of life for patients suffering from critical hematologic and oncological conditions.

For more information on the presentations, attendees can access the ASCO Annual Meeting abstracts and EHA2026 Congress materials via their respective digital platforms. Rigel continues to push the boundaries of treatment options, aligning with its mission to offer hope to patients in need.